| Autor: |
Clifton, Guy T., Sears, Alan K., Clive, Kevin S., Holmes, Jarrod P., Mittendorf, Elizabeth A., Ioannides, Constantine G., Ponniah, Sathibalan, Peoples, George E. |
| Zdroj: |
Human Vaccines; February 2011, Vol. 7 Issue: 2 p183-190, 8p |
| Abstrakt: |
Folate receptor alpha (FR α) is a membrane-bound transport protein with several features which make it an attractive target for cancer immunotherapy. FR α is largely shielded from the immune system in normal tissue but exposed while expressed on a variety of malignancies; it is functionally active in cancer pathogenesis; and it is immunogenic. A variety of different immunotherapeutic methods targeting FR α are being explored to treat cancer. Passive immunotherapy includes monoclonal antibodies, antibodies modified to deliver treatments, and modified T cell therapy. Active immunotherapy has focused on using FR α to increase the immunogenicity of cancer or to generate active FR α-directed immunity through a range of vaccination techniques. We will review the rationale behind targeting immunotherapy to FR α and cover the various techniques designed to do this. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
